key: cord-0705117-o3ycocki
authors: Villena-Vargas, Jonathan; Lutton, Evan M.; Mynard, Nathan; Nasar, Abu; Voza, Francesca; Chow, Oliver; Lee, Benjamin; Harrison, Sebron; Stiles, Brendon M.; Port, Jeffrey L.; Altorki, Nasser K.
title: Safety of Lung Cancer Surgery During COVID-19 in a Pandemic Epicenter
date: 2022-03-01
journal: J Thorac Cardiovasc Surg
DOI: 10.1016/j.jtcvs.2021.11.092
sha: 5c04cff84e14c5c253f1771e9688b728dd5e7f73
doc_id: 705117
cord_uid: o3ycocki

Objective The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on surgery for non small cell lung cancer (NSCLC) needs to be understood to inform clinical decision making during and after the COVID-19 pandemic. This study reports on the 90-day rate of infection as well as the morbidity and mortality of lung surgery for cancer in a tertiary care hospital located in a pandemic epicenter. Methods We conducted a retrospective review of a prospective database to identify consecutive patients who underwent lung cancer resection before (1/1/20-3/10/20, group 1; 57 patients) and during the COVID-19 pandemic (3/11-6/10/20, group 2; 41 patients). The primary endpoint was the occurrence of SARS-CoV-2 infection during the first 90-days after surgery. The secondary outcome measure was 90-day peri-operative morbidity and mortality. Results Patient characteristics were not significantly different between the groups. Ninety-day COVID-19 infection rates was 7.3% (3/41) for patients operated on during the pandemic and 3.5% (2/57) in patients operated on immediately prior to pandemic. All patients tested positive 10-62 days after the index surgical procedure following hospital discharge. Four COVID-19 positive patients were symptomatic and four out of five patients required hospitalization, were male, previous or current smokers with hyperlipidemia and underwent a sub-lobar resection. Univariate analysis did not identify any differences in post-operative complications before or during the COVID-19 pandemic. Ninety-day mortality was 5% (2/41) for lung cancer surgery performed during the pandemic, with all deaths occuring due to COVID-19, compared to 0% (0/57) mortality in patients operated on prior to the pandemic. Conclusions During the COVID-19 pandemic, COVID-19 infections occurred in 7.3% of patients who had surgery for NSCLC. In this series all infections occurred post-hospital discharge. Our results suggest that COVID-19 infections occurring within 90 days of surgery portend a 40% mortality, warranting close post-operative surveillance.

The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on surgery for non 65 small cell lung cancer (NSCLC) needs to be understood to inform clinical decision making during 66 and after the COVID-19 pandemic. This study reports on the 90-day rate of infection as well as 67 the morbidity and mortality of lung surgery for cancer in a tertiary care hospital located in a 68 pandemic epicenter. 69

We conducted a retrospective review of a prospective database to identify consecutive patients 71 who underwent lung cancer resection before (1/1/20-3/10/20, group 1; 57 patients) and during the 72 COVID-19 pandemic (3/11-6/10/20, group 2; 41 patients). The primary endpoint was the 73 occurrence of SARS-CoV-2 infection during the first 90-days after surgery. The secondary 74 outcome measure was 90-day peri-operative morbidity and mortality. 75

Results 76 Patient characteristics were not significantly different between the groups. Ninety-day COVID-19 77 infection rates was 7.3% (3/41) for patients operated on during the pandemic and 3.5% (2/57) in 78 patients operated on immediately prior to pandemic. All patients tested positive 10-62 days after 79 the index surgical procedure following hospital discharge. Four COVID-19 positive patients were 80 symptomatic and four out of five patients required hospitalization, were male, previous or current 81 smokers with hyperlipidemia and underwent a sub-lobar resection. Univariate analysis did not 82 identify any differences in post-operative complications before or during the COVID-19 83 pandemic. Ninety-day mortality was 5% (2/41) for lung cancer surgery performed during the 84 J o u r n a l P r e -p r o o f pre-pandemic and pandemic study groups are displayed. Cases who were infected with COVID-113 19 post-operatively are represented by pins (filled circles), indicating the date of surgery. 114

Coronavirus 2 (SARS-CoV-2) started in Wuhan One unique subset of cancer patients who may be at higher risk is comprised of those that require 142 lung resection for non-small-cell lung cancer (NSCLC). The risk-benefit ratio for these patients 143 must be carefully weighed, as contracting COVID-19 in the post-operative period confers a high 144 outcomes of surgical resection for lung cancer during the COVID-19 pandemic. The objective of 146 this study is to report the incidence and outcome of COVID-19 after surgical resection of lung 147 cancer in NYC during the COVID-19 pandemic. 148 149

We conducted a retrospective review of a prospectively assembled thoracic surgery database to 151 identify patients undergoing surgical resection for lung cancer clinically staged as Stage I to IIIA, 152 with or without preoperative induction therapy, between January 1st, 2020 to June 10, 2020. June 153 10, 2020 was chosen as it was the end of the first wave in New York (Figure 1 ). Patients were 154 catecogerized into two groups, pre-pandemic and pandemic in order to compare the surgical 155 outcomes while significant reallocation of resources took place. Group 1 was defined as the 156 patients operated on between January 1, 2020 and the day immediately prior to the start of the 157 pandemic as defined by the WHO to be March 11, 2020 (01/01/2020 to 03/10/2020). Group 2 was 158 defined as the pandemic period starting on March 11 through June 10 th , 2020 when COVID-19 159 cases in New York City had substantially decreased (Figure 1) including preoperative co-morbidities are shown in Table 1 . The majority were white, 70 years 224 old (age range 44-88) females with early-stage adenocarcinoma. There were no major differences 225 in co-morbidities between group 1 and group 2 except for a higher incidence of hypertension in 226 group 2 (p =0.008). There was no difference between the two groups in clinical stage distribution, 227 utilization of neoadjuvant therapy, or final pathological stage distribution. Resection was 228 accomplished with minimally invasive approaches (robotic or VATS) in 95% of patients in both 229 groups ( Table 2) . Lobar resections were performed in 62% of patients and an R-0 resection was 230 accomplished in all but one patient, occurring in group 1. There was no difference in major 231 complications between the two groups ( Table 3) . Four of the 5 re-operations were due to bleeding, 232 with one patient requiring reoperation for post-operative airleak. Overall readmission rates were 233 not statistically different between groups (p=0.541, Table 2 ). There were no in-hospital deaths in 234 either group. Average length of stay was 4 days (range 2-22 days). (Table 3) . Four out of five patients who tested positive for COVID-19 following lung resection 248 were male, previous or current smokers with hyperlipidemia and underwent a sub-lobar resection. 249

All were over the age of 65 with the average age being 72 years old (range 66-76) ( Table 4) . 250

Charlson Comorbidity Index (CCI) was calculated for patients who tested positive for COVID-19 251 following lung resection and was not predictive of mortality. Three patients had a CCI of 5, one 252 had CCI of 6, and one had CCI of 10. The patients that died of COVID-19 had CCI of 5 and 10. 253

No patient that later developed COVID-19 displayed respiratory symptoms or fever requiring 254 testing during the index hospitalization (Table 4 ). Two patients that tested positive for SARS-255

CoV2 died within 30 days of surgery, 3/5 patients that tested positive after 30 days fully recovered 256 at last follow-up and did not require long-term treatment for COVID-19 infection. Table 4 . Clinical characteristics for patients infected with COVID-19 and outcomes including Charlson Comorbidity Index (CCI), length of stay, post-operative day (POD) that COVID-19 was detected, and outcome (recovery vs death and post-operative day of death, POD#).

of Novel Coronavirus-Infected Pneumonia

Mortality During the COVID-19 Outbreak

Transforming ORs into ICUs

American College of Surgeons Covid-19 Communications

Committee BoR, Officers. The American College of Surgeons Responds to COVID-19

Epub 2020/07/17

Factors Associated With Surgical Mortality and Complications Among Patients With and Without 423

COVID-19) in Italy

Covid-19 and lung cancer: A greater fatality rate? Lung Cancer

Patients with Cancer Appear More 435 Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak

Epub 2020/04/30

Safety of patients and 439 providers in lung cancer surgery during the COVID-19 pandemic

Estimating the 443 infection-fatality risk of SARS-CoV-2

Perioperative Period of Lung Resection: A Brief Report From a Single Thoracic Surgery 453

People's Republic of China

COVID-19 in 457 patients with lung cancer

Surgical Resection on Short-Term and Long-Term Outcomes in Clinical Stage I Non-Small Cell

Lung Cancer

COVID-19 Guidance for Triage of Operations for Thoracic 467